US · ABEV · BEVERAGES - ALCOHOLIC
Ambev S.A. (ABEV) intrinsic value and stock valuation
$2.61as of 2026-11-21 · Mkt cap 46.82B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Ambev S.A. DCF and intrinsic value
InvestorsCraft values ABEV with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ABEV’s statements →
Ambev S.A. Graham Number
Graham Number: $11.27d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Target Corporation (TGT) $165.98
- Coca-Cola Europacific Partners PLC (CCEP) $115.53
- Keurig Dr Pepper Inc. (KDP) $34.84
- Sysco Corporation (SYY) $78.17
- Kenvue Inc. (KVUE) $19.31
- Kimberly-Clark Corporation (KMB) $106.38
- The Hershey Company (HSY) $175.48
- The Kroger Co. (KR) $68.44
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $88.2B | $89.5B | $79.7B | $79.7B | $72.9B |
| Operating income | $22.3B | $21.8B | $18.8B | $17.7B | $17.1B |
| Net income | $15.5B | $14.4B | $14.5B | $14.5B | $12.7B |
| EPSd | $988.5K | $912.9K | $915.6K | $912.2K | $799.1K |
| Operating cash flow | $24.5B | $26.1B | $24.7B | $20.6B | $22.9B |
| Capital expenditure | -$-4.59B | -$-4.75B | -$-6B | -$-6.53B | -$-7.68B |
| Free cash flow | $19.9B | $21.3B | $18.7B | $14.1B | $15.2B |
| Total assets | $148.1B | $162.5B | $132.6B | $138B | $138.6B |
| Total debt | $5.35B | $3.45B | $3.5B | $3.85B | $3.13B |
| Net debt | -$-13.29B | -$-25.14B | -$-12.56B | -$-11.08B | -$-13.5B |
| Total equity | $88.8B | $99.6B | $80.1B | $83.3B | $84B |
| Cash and short-term investments | $20.3B | $29.8B | $16.3B | $15.4B | $18.5B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $88.2B | $89.5B | $79.7B | $79.7B | $72.9B |
| Cost of revenue | $42.9B | $43.6B | $39.3B | $40.4B | $35.7B |
| Gross profit | $45.4B | $45.8B | $40.4B | $39.3B | $37.2B |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $25.1B | $26.4B | $23.4B | $24B | $21.8B |
| Other expenses | -$-2.08B | -$-2.36B | -$-1.82B | -$-2.37B | -$-1.73B |
| Operating expenses | $23.1B | $24B | $21.6B | $21.6B | $20.1B |
| Cost and expenses | $65.9B | $67.7B | $60.9B | $62B | $55.8B |
| Interest income | $1.4B | $1.62B | $417.6M | $419.7M | $1.14B |
| Interest expense | $2.72B | $2.4B | $578.4M | $596.1M | $1.43B |
| Depreciation and amortization | $6.83B | $7.13B | $6.42B | $5.96B | $5.4B |
| Ebitda | $29B | $29B | $24.3B | $23.1B | $21B |
| Operating income | $22.3B | $21.8B | $18.8B | $17.7B | $17.1B |
| Total other income/expenses, net | -$-2.9B | -$-2.31B | -$-3.8B | -$-3.45B | -$-3.32B |
| Income before tax | $19.4B | $19.5B | $15B | $14.2B | $13.8B |
| Income tax expense | $3.43B | $4.64B | $75.5M | -$-655.6M | $636.6M |
| Net income | $15.5B | $14.4B | $14.5B | $14.5B | $12.7B |
| Weighted average shares outstanding | $15.6B | $15.8B | $15.8B | $15.7B | $15.7B |
| Weighted average diluted shares outstanding | $15.7B | $15.8B | $15.8B | $15.8B | $15.9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $20.3B | $29.8B | $16.3B | $15.4B | $18.5B |
| Net receivables | $10.2B | $9.85B | $9.18B | $8.2B | $4.79B |
| Inventory | $10.5B | $11.7B | $9.62B | $12.9B | $11B |
| Total current assets | $43.9B | $54.2B | $36.6B | $37.8B | $38.6B |
| Property, plant and equipment, net | $27.6B | $30.2B | $26.6B | $30.1B | $29.2B |
| Goodwill and intangible assets | $52.6B | $56.9B | $48B | $49.8B | $51.1B |
| Long-term investments | $1.26B | $579.9M | $531.3M | $551M | $498.1M |
| Total non-current assets | $104.2B | $108.4B | $96.1B | $100.1B | $100B |
| Total assets | $148.1B | $162.5B | $132.6B | $138B | $138.6B |
| Accounts payable | $22.6B | $25.2B | $23.2B | $24.3B | $25.1B |
| Short-term debt | $1.17B | $1.28B | $1.3B | $1.06B | $877.6M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $45.6B | $49.4B | $41B | $40.5B | $38.9B |
| Long-term debt | $4.18B | $2.18B | $2.2B | $2.79B | $2.25B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $13.7B | $13.5B | $11.5B | $14.1B | $15.7B |
| Capital lease obligations | $1.96B | $2.97B | $2.96B | $3.12B | $2.64B |
| Total liabilities | $59.3B | $62.9B | $52.5B | $54.6B | $54.6B |
| Common stock | $58.3B | $58.2B | $58.2B | $58.1B | $58B |
| Retained earnings | $18B | $0.00 | $0.00 | $0.00 | $0.00 |
| Accumulated other comprehensive income (loss) | $14.6B | $109B | $98.7B | $92.2B | $86.4B |
| Total equity | $88.8B | $99.6B | $80.1B | $83.3B | $84B |
| Total investments | $2.94B | $1.82B | $808.5M | $1.01B | $2.41B |
| Total debt | $5.35B | $3.45B | $3.5B | $3.85B | $3.13B |
| Net debt | -$-13.29B | -$-25.14B | -$-12.56B | -$-11.08B | -$-13.5B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $16B | $14.8B | $15B | $14.9B | $13.1B |
| Depreciation and amortization | $6.83B | $7.13B | $6.42B | $5.96B | $5.4B |
| Stock-based compensation | $454.2M | $400.9M | $331.6M | $313.9M | $387.6M |
| Change in working capital | -$-1.62B | -$-165M | -$-296.1M | -$-2.68B | $3B |
| Accounts receivable | -$-312.9M | $220.4M | -$-1.37B | -$-322.5M | $341.4M |
| Inventory | -$-30.9M | -$-1.7B | $1.3B | -$-3.09B | -$-3.5B |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $24.5B | $26.1B | $24.7B | $20.6B | $22.9B |
| Investments in property, plant and equipment | -$-4.59B | -$-4.75B | -$-6B | -$-6.53B | -$-7.68B |
| Acquisitions, net | -$-91.6M | $10.3M | -$-52.8M | -$-33M | -$-133.3M |
| Net cash used for investing activities | -$-4.95B | -$-5.46B | -$-5.77B | -$-5B | -$-7.74B |
| Common stock issued | $0.00 | $17.5M | $14.5M | $23.8M | $9.1M |
| Common stock repurchased | -$-1.93B | -$-467.6M | -$-119M | -$-54.1M | -$-44.2M |
| Dividends paid | -$-20.46B | -$-4.06B | -$-11.92B | -$-12.24B | -$-11.12B |
| Net cash used for financing activities | -$-26.77B | -$-10.35B | -$-16.12B | -$-16.34B | -$-16.04B |
| Net change in cash | -$-9.96B | $12.5B | $1.21B | -$-1.75B | -$-493.1M |
| Cash at end of period | $18.6B | $28.6B | $16.1B | $14.9B | $16.6B |
| Operating cash flow | $24.5B | $26.1B | $24.7B | $20.6B | $22.9B |
| Capital expenditure | -$-4.59B | -$-4.75B | -$-6B | -$-6.53B | -$-7.68B |
| Free cash flow | $19.9B | $21.3B | $18.7B | $14.1B | $15.2B |
Line items
Line items
Line items
About Ambev S.A.
Ambev S.A., operating through its various subsidiaries, is a prominent player in the beverage and food industry across the Americas. The company is engaged in the manufacturing, marketing, and distribution of a diverse portfolio of products, including various types of beer (both packaged and on tap), carbonated soft drinks, other non-alcoholic beverages, malt, and food items. Its extensive operations are structured into four primary geographical divisions: Brazil; Central America and the Caribbean; Latin America South; and Canada. Ambev's vast selection of beer labels features widely recognized names such as Skol, Brahma, Antarctica, Brahva, Brahva Gold, Extra, Bud Light, Beck, Leffe, Hoegaarden, Bucanero, Cristal, Mayabe, Cacique, Presidente, Brahma Light, Presidente Light, Presidente Golden Light, Bohemia, The One, Corona, Modelo Especial, Stella Artois, Budweiser, Quilmes Clásica, Paceña, Taquiña, Huari, Becker, Cusqueña, Michelob Ultra, Busch, Pilsen, Ouro Fino, Banks, Deputy, Patricia, Labatt Blue, Alexander Keith's, and Kokanee. Beyond alcoholic offerings, the company also provides a comprehensive range of non-alcoholic drinks. These include bottled water, isotonic and energy beverages, coconut water, powdered and natural fruit juices, and ready-to-drink teas. These products are sold under popular brands like Guaraná Antarctica, Gatorade, H2OH!, Lipton Iced Tea, Fusion, Do Bem, Pepsi, Canada Dry, Squirt, Red Rock, Pepsi-Cola, Seven Up, Nutrl, Bud Light Seltzer, Palm Bay, and Mike's. Products are made available to consumers through a multifaceted distribution approach, combining its own direct distribution network with a system that leverages third-party distributors. Ambev S.A. was founded in 1885 and maintains its corporate headquarters in São Paulo, Brazil. It operates as a subsidiary of Interbrew International B.V.
- CEO
- Carlos Eduardo Klutzenschell Lisboa
- Employees
- 39K
- Beta
- 0.27
Explore
Frequently asked questions
What is the intrinsic value of Ambev S.A. (ABEV)?
Ambev S.A. (ABEV) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ABEV undervalued?
ABEV trades at a price of $2.61 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.